Semaglutide, the active ingredient in Ozempic, and other drugs in the same class have revolutionized the treatment of obesity and type 2 diabetes.Now, a clinical trial suggests the medicines can ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed. In this 26-week, double-blind trial of 72 adults, 36% ...

A new study finds the use of weight loss drugs like Ozempic, Wegovy, and Zepbound in people with Type-1 Diabetes has risen sharply. It comes even though there's little information on the drugs ...

More people with type 1 diabetes are using GLP-1s like Ozempic and Zepbound, a new study found. Researchers attribute the high demand to rising rates of obesity among people with type 1 diabetes.

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related cancers, especially colorectal cancer, according to data released on ...

A cure for diabetes has been top of mind for many that live with the conditions under the term’s umbrella. But type 1 diabetes, in particular, is an irreversible lifelong autoimmune condition.

Researchers have 3D printed devices made of insulin-producing cells. These devices could enable a long-term treatment for type 1 diabetes that would let people produce their own insulin ...

Western Sydney University researchers have led a global team to pioneer a new AI-powered tool to assess the risk of developing type 1 diabetes (T1D) and predict treatment responses, potentially ...

Learn how type 1 and type 2 diabetes differ in causes, onset, and management strategies. Expert insights on symptoms, treatment, and lifestyle adaptations.

Dual-action approach targeting inflammation shows potential as Type 1 diabetes treatment. ScienceDaily . Retrieved July 23, 2025 from www.sciencedaily.com / releases / 2025 / 05 / 250507141132.htm ...